| 前收市價 | 88.09 |
| 開市 | 87.95 |
| 買盤 | 86.69 x 300 |
| 賣出價 | 86.77 x 300 |
| 今日波幅 | 86.15 - 88.24 |
| 52 週波幅 | 85.21 - 125.83 |
| 成交量 | |
| 平均成交量 | 593,175 |
| 市值 | 20.896B |
| Beta 值 (5 年，每月) | 0.23 |
| 市盈率 (最近 12 個月) | 21.15 |
| 每股盈利 (最近 12 個月) | 4.10 |
| 業績公佈日 | 2024年5月06日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 2022年6月02日 |
| 1 年預測目標價 | 118.53 |
- Reuters
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
ReutersGlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
ReutersPfizer vs Moderna battle over COVID vaccine patents begins in UK
Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday. Pfizer and its German partner BioNTech sued Moderna at London's High Court in September 2022, seeking to revoke patents held by Moderna, which hit back days later alleging its patents had been infringed. Moderna says Pfizer and BioNTech copied mRNA advances it had pioneered and patented well before the COVID-19 pandemic began in late 2019.
